Clariant: Market demand drives investment

During the recent World Pharmaceutical Raw Materials China Exhibition (CPhI), Clariant announced that it would increase its investment in China's medical packaging market to meet growing market demand. Matthias Brommer, Clariant's vice president and general manager of the medical packaging business chain, said: 'This represents Clariant's commitment and confidence in the Chinese market and shows that Clariant sees the Chinese market as an important part of its global market and that its importance is growing.'
market and breadth
As the world's leading provider of medical packaging, Clariant's medical packaging business chain serves 85% of the world's medical customers, with a annual production capacity of 5 billion

. At present, Clariant's global active packaging market sales of about 500 million euros, including absorbent oxygen absorption, water resistance, oxygen blocking packaging, and this market growth is very active, the average growth rate over the past four to five years is 7% to 9%. Among them, the Chinese market is very important.
that the Chinese market has a breadth that is unmatched by other markets. In such markets, Clariant is able to provide packaging for pharmaceuticals, medical devices and nutritional supplements, while in other markets the demand for packaging is so limited that the company can only offer certain varieties of packaging. The Chinese market has created good conditions for Clariant's development. At the same time, demand in the Chinese market is growing at an alarming rate. This market speed places high demands on both product applications and lead times and product changes.
He said Clariant's medical packaging business chain has formed a global layout, with factories in Belen, New Mexico, Roman Rotin, China Changshu, Dongguan and Goodlor, India, with strong local supply capabilities. These five plants produce products that are anti-degradation agents, primarily for water- and oxygen-sensitive drugs, providing customers with protective packaging systems and global business support, laying the foundation for the company's sustainable goals. Clariant's pharmaceutical packaging and medical device packaging materials business in China is mainly aimed at local chinese customers, most of the products are locally manufactured, local sales, export proportion is very small. Although the form of international trade has changed, the impact on Clariant's Chinese market has been limited.
Resuming to increase market investment
In view of the future development of the Chinese market, Mr. Ma said that in order to meet the development needs of the Chinese market, Clariant's medical packaging business chain will increase its investment in the Chinese market and realize its commitment to the Chinese market. He revealed that Clariant's medical packaging business chain has developed a five-year development plan, the Chinese market will get a relatively large proportion of investment. These investments will provide clariant with a driving force for accelerated growth in China.
stressed that Clariant's medical packaging business has entered China for a decade and has seen the Chinese pharmaceutical market flourish. In this development, the market presents an urgent need for innovation, quality and safety of pharmaceutical packaging, and these needs are increasing day by day. At present, Clariant has an independent research and development team at Changshu plant, focusing on the development of pharmaceutical plastic packaging systems, new product design and mold design for product design, and for the application of packaging to develop functional materials and fully automatic assembly equipment.
Clariant's research and development is a two-step process, the first is to be close to customers, listen carefully to their ideas, opinions, pain points and problems, from which to find innovation points. The second is to allow scientists to innovate strategically through the Paris Research Centre, proposing ideas that are five to 10 years earlier than market demand, as evidenced by the balanced moisture-absorbing desiccant. Innovation is a two-way street, says Mr Madelean, and listening to customer needs is on the one hand, and independent innovation by scientists on the other.
emphasis on customized services
as an innovative-driven package supplier, Clariant focuses on customized development in the innovation process. In order to meet the innovative requirements of our customers, Clariant provides our customers with supporting services and support tools for humidity evaluation, water vapor analysis, and the use of StablusTM (Life Prediction Simulation System) predictive simulations to measure shelf life.
said Clariant had set up an experimental workshop dedicated to sample testing for customers. From product development to eventual large-scale mass production, Clariant has a strong automation design capability to ensure the implementation of customized services.
He explains that Clariant has a large amount of basic research data, theoretical data evaluation and a complete shelf life data simulation system to ensure that when customers choose packaging materials, the shelf life of packaging materials can be judged on the basis of the results of the relative experiments. Based on a large amount of basic research data, scientists can also specialize in packaging protection against drugs. Scientists can use the set of computational experience software to assess the different needs of customers and different packaging forms, so as to determine the amount, type and duration of desiccant protection, to provide customers with accurate customization services.